|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.7550 USD | +3.42% |
|
-48.20% | -20.46% |
| 16/01 | Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing | RE |
| 06/01 | Jaguar Health, Inc. announced that it has received $0.35 million in funding | CI |
| Capitalization | 33.12L 28.17L 26.11L 24.4L 45.49L 30Cr 48.21L 2.98Cr 1.18Cr 14Cr 1.24Cr 1.22Cr 52Cr | P/E ratio 2025 * |
-0.07x | P/E ratio 2026 * | -0.23x |
|---|---|---|---|---|---|
| Enterprise value | -16.9L -14.37L -13.32L -12.45L -23.21L -16Cr -24.6L -1.52Cr -60.44L -7.33Cr -63.37L -62.07L -27Cr | EV / Sales 2025 * |
-0.13x | EV / Sales 2026 * | -0.09x |
| Free-Float |
81.66% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Jaguar Health, Inc.
More press releases
| 1 day | +4.11% | ||
| 1 week | -48.20% | ||
| Current month | -20.46% | ||
| 1 month | -32.05% | ||
| 3 months | -62.78% | ||
| 6 months | -68.88% | ||
| Current year | -20.46% |
| 1 week | 0.68 |  | 1 |
| 1 month | 0.64 | | 1.87 |
| Current year | 0.64 | | 1.87 |
| 1 year | 0.64 | | 25.75 |
| 3 years | 0.64 | | 8,114.98 |
| 5 years | 0.64 | | 10,00,000 |
| 10 years | 0.64 | | 10,00,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lisa Conte
CEO | Chief Executive Officer | 67 | 06/06/2013 |
Carol Lizak
DFI | Director of Finance/CFO | 62 | 13/08/2019 |
Jonathan Wolin
CMP | Compliance Officer | 64 | 01/11/2018 |
| Director | Title | Age | Since |
|---|---|---|---|
Lisa Conte
BRD | Director/Board Member | 67 | 06/06/2013 |
James Bochnowski
CHM | Chairman | 82 | 01/06/2014 |
John Micek
BRD | Director/Board Member | 73 | 01/04/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.42% | -48.20% | -96.40% | -99.99% | 33.12L | |
| -2.02% | +2.71% | +39.12% | +211.65% | 97TCr | |
| -0.23% | -0.24% | +48.75% | +29.60% | 53TCr | |
| -0.40% | +1.64% | +27.66% | +46.67% | 39TCr | |
| +0.06% | -0.23% | +26.86% | +17.82% | 38TCr | |
| +0.15% | -3.36% | +22.94% | +23.03% | 28TCr | |
| +0.47% | +0.03% | +28.12% | +35.36% | 28TCr | |
| +1.17% | +3.20% | -30.92% | -16.86% | 28TCr | |
| -1.34% | -1.20% | +11.27% | -2.15% | 27TCr | |
| -1.40% | +3.86% | +23.50% | +31.50% | 19TCr | |
| Average | -0.02% | +1.09% | +10.09% | +27.66% | 35.6TCr | |
| Weighted average by Cap. | -0.75% | +2.10% | +27.46% | +73.99% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.26Cr 1.07Cr 98.98L 92.5L 1.72Cr 115.36Cr 1.83Cr 11Cr 4.49Cr 54Cr 4.71Cr 4.61Cr 198.13Cr | 2.65Cr 2.26Cr 2.09Cr 1.96Cr 3.65Cr 243.91Cr 3.86Cr 24Cr 9.5Cr 115.16Cr 9.95Cr 9.75Cr 418.91Cr |
| Net income | -2.98Cr -2.53Cr -2.35Cr -2.19Cr -4.09Cr -273.7Cr -4.34Cr -27Cr -11Cr -129.23Cr -11Cr -11Cr -470.07Cr | -1.44Cr -1.22Cr -1.14Cr -1.06Cr -1.98Cr -132.31Cr -2.1Cr -13Cr -5.15Cr -62Cr -5.4Cr -5.29Cr -227.23Cr |
| Net Debt | -50.02L -42.54L -39.43L -36.85L -68.69L -46Cr -72.81L -4.51Cr -1.79Cr -22Cr -1.88Cr -1.84Cr -79Cr | -55.91L -47.55L -44.08L -41.19L -76.78L -51Cr -81.38L -5.04Cr -2Cr -24Cr -2.1Cr -2.05Cr -88Cr |
More financial data
* Estimated data
Employees
49
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/26/23 | 0.7407 $ | +1.47% | 7,58,617 |
| 22/26/22 | 0.7300 $ | -9.78% | 61,06,270 |
| 21/26/21 | 0.8091 $ | -5.37% | 21,83,770 |
| 20/26/20 | 0.8550 $ | -40.21% | 79,11,853 |
| 16/26/16 | 1.430 $ | +87.05% | 16,04,02,168 |
Delayed Quote Nasdaq, January 23, 2026 at 11:10 pm IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.7300USD
Average target price
25.50USD
Spread / Average Target
+3,393.15%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JAGX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition